STOCK TITAN

2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

2seventy bio, Inc. (NASDAQ: TSVT) announced its participation in the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference. The event will take place on June 14, 2022, at 3:20 pm PT in Rancho Palos Verdes, CA. A live webcast will be available through the Investors and Media section of the company’s website, with an archived replay accessible for 30 days post-event. 2seventy bio is committed to pioneering cell therapies to enhance cancer treatment and focuses on delivering innovative therapies aimed at various hematologic malignancies and solid tumors.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 3:20pm PT.

A live webcast will be available via the Investors and Media section of 2seventy bio’s website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio’s site for 30 days following the event.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: Twitter and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

Investors:

Elizabeth Pingpank, 860-463-0469

elizabeth.pingpank@2seventybio.com

Media:

Victoria Wagner (von Rinteln), 703-599-2868

victoria.wagner@2seventybio.com

Morgan Adams, 774-313-9852

morgan.adams@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

When will 2seventy bio participate in the Goldman Sachs Global Healthcare Conference?

2seventy bio will participate in the conference on June 14, 2022, at 3:20 pm PT.

Where will the Goldman Sachs Global Healthcare Conference be held?

The conference will take place in Rancho Palos Verdes, CA.

How can I watch the 2seventy bio conference live?

You can watch the live webcast on the Investors and Media section of 2seventy bio’s website.

How long will the 2seventy bio conference replay be available?

The replay of the conference will be archived for 30 days after the event.

What is the focus of 2seventy bio's research and development?

2seventy bio focuses on developing immuno-oncology cell therapies for hematologic malignancies and solid tumors.

2seventy bio, Inc.

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Stock Data

155.75M
49.50M
4.05%
90.75%
9.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE